Evidence map›Paper›PMID 39842889›Full record

ReviewBMJ case reports2025

Gemcitabine-induced myositis in a patient with pancreatic cancer.

Zach Rubnitz, Chris Nevala-Plagemann, Vaia Florou, Ignacio Garrido-Laguna

Abstract readCase ReportsReview
In one paragraph

Review in BMJ case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zach RubnitzInternal Medicine, University of Utah Health, Salt Lake City, Utah, USA Zach.Rubnitz@hsc.utah.edu.ORCID http://orcid.org/0009-0007-7370-4075
Chris Nevala-PlagemannMedical Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA.
Vaia FlorouMedical Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA.ORCID http://orcid.org/0000-0001-5558-753X
Ignacio Garrido-LagunaMedical Oncology, Huntsman Cancer Institute Cancer Hospital, Salt Lake City, Utah, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gemcitabine, a cytosine analogue, is a cytotoxic agent commonly used in the treatment of patients with a variety of solid tumours, including non-small cell lung cancer, cholangiocarcinoma and breast, pancreatic, testicular and ovarian cancers. Although generally well-tolerated, several reports suggest that it can rarely cause myositis. We present a case of gemcitabine-induced myositis in a patient with pancreatic adenocarcinoma and review the literature on this topic.

Indexed as

AdenocarcinomaAntimetabolites, AntineoplasticDeoxycytidineMyositisPancreatic NeoplasmsAgedGemcitabineHumansMaleMiddle AgedAntimetabolites, AntineoplasticDeoxycytidineGemcitabineChemotherapyPancreatic cancerUnwanted effects / adverse reactions

Identifiers

PMID39842889
PMCPMC11759102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.